We are conducting two 3 hour in-person workshops with young adults who consume alcohol to support the development of an intervention which uses social medial to address the link between alcohol use and cancer risk.

Are you battling triple-negative breast cancer? If your cancer has come back or spread, and you haven't started treatment yet, you might qualify for a clinical trial testing a new medication. Discover more about this opportunity to find a potentially better treatment option.

Have you diagnosed with lymph node positive early breast cancer, have received surgery, and have not received any systemic or radiation treatment prior to surgery? If so, you may be able to take part in this clinical trial which seeks to improve the treatment of early-stage breast cancer by examining ctDNA, a biomarker found in the blood that may indicate the presence of disease. This study aims to determine if ctDNA can help doctors personalize therapies leading to more effective treatment plans.

Have you been diagnosed with Leukemia? Do you have a functioning kidney, liver, and cardiac organ? If so, you may be able to participate in a study on a new drug called LBS-007. We want to find out if it is safe for people with Leukemia. Compensation provided.

Do you have acid reflux, GERD, or Barrett's Esophagus? Are you having standard of care endoscopies performed? You may be able to participate in a research study testing for Barrett's Esophagus and esophageal cancer. Compensation provided.

Have you been diganosed with epithelial high grade ovarian, fallopian tube or primary peritoneal carcinoma? if so, you may be able to participate in this research study to evaluate if the combination of Trastuzumab Deruxtecan (T-DXd) and Bevacizumab works better than bevacizumab alone for the treatment of your type of cancer.

Have you been diagnosed with Metastatic Colorectal Cancer? If so, you might be able to take part in a study to see if an investigational product is safe and effective for treating metastatic colorectal cancer.

The purpose of this research is to test the safety of NXC-201 (a CAR-T cell targeting the BCMA protein) at different doses in participants with relapsed/refractory AL amyloidosis, and to confirm the best dose for further testing. In addition, the study will evaluate the effectiveness of NXC-201 in treating relapsed/refractory AL amyloidosis

The purpose of this study is to determine if epcoritamab can be used to treat patients with previously treated WM.

The purpose of this study is to test the effectiveness and safety of the combination of an investigational vaccine, PDS0101, and the standard of care, compared to the standard of care treatment alone.